What's Happening?
RQM+, a MedTech CRO specializing in regulatory consulting, clinical trials, laboratory services, and reimbursement, has launched an AI Center of Excellence (CoE). This new initiative aims to assist companies in meeting the regulatory, clinical, and quality
requirements for AI-enabled medical devices and in vitro diagnostics (IVDs). The AI CoE integrates expertise in AI, regulatory affairs, clinical practices, and IVDs from across RQM+ to support companies as AI adoption in MedTech outpaces regulatory clarity. The center will address new requirements introduced by the EU Artificial Intelligence Act (AI Act), in addition to existing EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). The CoE will provide guidance to AI and software developers new to device regulation, manufacturers incorporating AI into their processes, and device makers integrating AI into complex devices. Bethany Chung, Ph.D., head of the AI Center of Excellence, highlighted that many software developers may not realize their products are regulated as medical devices or IVDs, emphasizing the need for expert guidance from the outset.
Why It's Important?
The establishment of RQM+'s AI Center of Excellence is crucial for the U.S. MedTech industry, particularly for companies developing AI-enabled medical devices and diagnostics. As AI technology rapidly advances, the regulatory landscape, both domestically and internationally, struggles to keep pace. This creates significant challenges for innovators seeking to bring their products to market. The CoE will help U.S. companies navigate complex regulatory frameworks, such as the EU's AI Act, MDR, and IVDR, which often influence global standards and market access. Without clear guidance, companies risk delays in product approval, increased development costs, and potential non-compliance, which could stifle innovation and limit patient access to advanced diagnostic tools. By providing specialized expertise, RQM+ aims to streamline the regulatory process, ensuring that AI-driven medical technologies can be developed and deployed safely and effectively, ultimately benefiting patient care and fostering growth within the MedTech sector.
What's Next?
The RQM+ AI Center of Excellence is poised to become a key resource for MedTech and software companies grappling with the evolving regulatory environment for AI-enabled medical devices. The CoE will continue to offer guidance on classification, regulatory pathways, clinical evidence, and technical documentation, particularly for software as a medical device (SaMD) and IVDs. Companies can expect ongoing support for ensuring AI-assisted activities comply with quality standards like ISO 13485 and for developing combined device and AI regulatory strategies for complex products. As regulatory bodies, including those in the U.S., continue to refine their approaches to AI in healthcare, the demand for specialized expertise in this area is likely to grow. The CoE's proactive approach aims to prepare companies for future regulatory changes and facilitate the responsible integration of AI into medical devices, ensuring that innovation can proceed without compromising patient safety or regulatory compliance.
Beyond the Headlines
The launch of RQM+'s AI Center of Excellence underscores a broader, critical challenge facing the healthcare technology sector: the rapid advancement of AI often outpaces the development of comprehensive regulatory frameworks. This gap raises significant ethical and legal questions regarding accountability, data privacy, and algorithmic bias in AI-driven diagnostics. While AI promises enhanced accuracy and efficiency, ensuring its responsible deployment requires robust oversight and clear guidelines. The CoE's focus on regulatory compliance is not merely about meeting legal requirements but also about building public trust in AI-enabled medical devices. The long-term implications include the potential for a more standardized and globally harmonized approach to AI regulation in healthcare, which could accelerate the adoption of life-saving technologies while mitigating risks. This initiative highlights the growing need for interdisciplinary expertise that bridges technological innovation with regulatory foresight and ethical considerations.













